Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityPTX / Pernix Therapeutics Holdings, Inc. (71426V108)
Chairman of the Board & CEOSedor John A
IndustryPharmaceutical Preparations
Institutional Owners39
Institutional Shares2,268,726 - 19.11%
Common Shares Outstanding11,873,562 shares (as of 2018-03-31)
Institutional Value$ 5,341,000 USD
Related 71426VAK4 / Pernix Therapeutics Holdings, Inc. Convertible Debt 4.25%
71426VAJ7 / Pernix Therapeutics Holdings, Inc. Debt 4.25%

Institutional Stock Ownership and Shareholders()

PTX / Pernix Therapeutics Holdings, Inc. Institutional Ownership

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) has 39 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,268,726 shares. Largest shareholders include Renaissance Technologies LLC, Vanguard Group Inc, Aisling Capital LLC, BlackRock Inc., BlackRock Institutional Trust Company, N.A., Jacobs Levy Equity Management, Inc, Bank Of Montreal /can/, Bank Of Montreal /can/, Cetera Investment Advisers, and Virtu Financial LLC.
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/ptx"><img src="https://images.fintel.io/us-ptx-so.png" alt="PTX / Pernix Therapeutics Holdings, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 3,000 63,000 2,000.00 7 153 2,085.71
2018-05-15 13F-HR JACOBS LEVY EQUITY MANAGEMENT, INC 73,421 79,921 8.85 176 191 8.52
2018-04-26 13F-HR SIMPLEX TRADING, LLC Call 28 4 -85.71 0 0
2018-05-15 13F-HR VANGUARD GROUP INC 327,490 373,449 14.03 786 892 13.49
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 39,813 39,595 -0.55 95 94 -1.05
2018-07-18 13F-HR Bedel Financial Consulting, Inc. 7 7 0.00 0 0
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Put 0 1,500 0 4
2018-05-14 13F-HR MORGAN STANLEY 14,209 2,089 -85.30 34 5 -85.29
2018-05-14 13F-HR Virtu Financial LLC 46,610 111
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 96 1,102 1,047.92 0 3
2018-04-26 13F-HR SIMPLEX TRADING, LLC Put 0 1 0 0
2018-05-08 13F-HR SIGNATUREFD, LLC 96 0
2017-02-10 13F-HR BlackRock Advisors LLC 7,631 763 -90.00 5 1 -80.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 1,610,542 161,054 -90.00 1,002 312 -68.86
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 82,838 0 -100.00 199 0 -100.00
2018-05-15 13F-HR WOLVERINE TRADING, LLC Put 15,400 15,900 3.25 37 38 2.70
2018-05-10 13F-HR Stratos Wealth Partners, LTD. 5 0
2018-05-09 13F-HR Cetera Investment Advisers 46,750 46,750 0.00 112 112 0.00
2018-05-14 13F-HR Evercore Wealth Management, LLC 5 0 -100.00 0 0
2018-05-10 13F-HR JP Morgan Chase & Co 100 0 -100.00 0 0
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 176 176 0.00 0 0
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 14 14 0.00 0 0
2018-05-14 13F-HR/A CITADEL ADVISORS LLC Call 11,500 15,700 36.52 28 38 35.71
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ Put 3,000 63,000 2,000.00 7 153 2,085.71
2018-05-09 13F-HR NORTHERN TRUST CORP 12,535 12,435 -0.80 30 29 -3.33
2018-05-14 13F-HR BOOTHBAY FUND MANAGEMENT, LLC 10,330 0 -100.00 25 0 -100.00
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. Call 1,100 5,400 390.91 3 13 333.33
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 17,700 0 -100.00 42 0 -100.00
2018-05-09 13F-HR BlackRock Inc. 209,380 209,448 0.03 502 500 -0.40
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 33,742 15,124 -55.18 81 36 -55.56
2018-05-15 13F-HR WOLVERINE TRADING, LLC Call 19,900 0 -100.00 48 0 -100.00
2018-05-11 13F-HR SEI INVESTMENTS CO 0 5 0 0
2017-01-13 13F-HR MetLife Securities, Inc 123 13 -89.43 0 0
2018-07-19 13F-HR Searle & Co. 13,325 13,325 0.00 32 32 0.00
2018-04-19 13F-HR VALLEY NATIONAL ADVISERS INC 6 6 0.00 0 0
2018-05-11 13F-HR CITADEL ADVISORS LLC Call 15,700 38
2018-05-15 13F-HR ARMISTICE CAPITAL, LLC 21,760,000 0 -100.00 9,175 0 -100.00
2018-05-15 13F-HR Advisor Group, Inc. 177 177 0.00 0 0
2018-05-15 13F-HR UBS Group AG 1,638 6,516 297.80 4 16 300.00
2018-05-14 13F-HR Renaissance Technologies LLC 914,750 941,250 2.90 2,195 2,250 2.51
2018-05-16 13F-HR/A GROUP ONE TRADING, L.P. 13,120 9,585 -26.94 31 23 -25.81
2018-05-15 13F-HR BARCLAYS PLC 58 61 5.17 0 0
2018-05-14 13F-HR Aisling Capital LLC 210,000 210,000 0.00 504 502 -0.40
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 103 103 0.00 0 0
2018-05-15 13F-HR DEUTSCHE BANK AG\ 1 1 0.00 0 0
2018-04-26 13F-HR SIMPLEX TRADING, LLC 0 1,703 0 4
2018-05-15 13F-HR Shanda Payment Holdings Ltd. 1,000 1,000 0.00 2 2 0.00
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 14,897 15,701 5.40 36 38 5.56
2018-05-15 13F-HR Nelson, Van Denburg & Campbell Wealth Management Group, LLC 70 70 0.00 0 0
2017-02-10 13F-HR BlackRock Fund Advisors 135,144 17,315 -87.19 84 34 -59.52
2018-05-09 13F-HR IFP Advisors, Inc 250 250 0.00 1 1 0.00
2018-05-14 13F-HR NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 0 7 0 0
PTX : Pernix Therapeutics Holdings Stock Analysis and Research Report

2017-10-16 - Asif

Pernix Therapeutics is a specialty pharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. Its strategy is to continue to create shareholder value by: growing sales of the existing products in its portfolio in various ways, including identifying new growth opportunities; and acquiring additional marketed specialty products or products close to regulatory approval to leverage its existing expertise and infrastructure. Pernix Therapeutics target underserved segments, such as central nervous system (CNS) indications, including neurology, pain and psychiatry. The company promote its core branded products to physicians through its sales forces. The company market its generic products through its wholly owned subsidiaries, Macoven and Cypress. Its branded products include Treximet, a medication indicated for the acute treatment of migraine attacks, with or without aura, ...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Pernix Therapeutics' (PTX) CEO John Sedor on Q1 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Pernix Therapeutics Holdings, Inc. (NYSEMKT:PTX) Q1 2018 Earnings Conference Call May 10, 2018 4:30 PM ET (28-1)

Orexigen Enters into Agreement to Sell Company to Newly Formed Entity Nalpropion Pharmaceuticals

2018-04-24 biospace
One month after filing for bankruptcy anti-obesity company Orexigen Therapeutics, Inc. could be acquired by the newly-formed company Nalpropion Pharmaceuticals, Inc. for $75 million in cash. (28-6)

BRIEF-Pernix Therapeutics Announces Participation In Lead Bid Worldwide Rights Of Contrave

2018-04-23 reuters
* PERNIX THERAPEUTICS ANNOUNCES PARTICIPATION IN LEAD BID FOR ACQUISITION OF WORLDWIDE RIGHTS TO CONTRAVE® FOR WEIGHT LOSS (21-0)

BRIEF-Pernix Therapeutics - Expects To Resume Distribution Of 20 Mg Dosage Strength Of Zohydro ER With Beadtek

2018-03-27 reuters
* PERNIX THERAPEUTICS HOLDINGS - EXPECTS TO RESUME DISTRIBUTION OF 20 MG DOSAGE STRENGTH OF ZOHYDRO ER (HYDROCODONE BITARTRATE) WITH BEADTEK ON MARCH 28 Source text for Eikon: Further company coverage: ([email protected]) (21-1)

CUSIP: 71426V108